Cygnus launches Biographer in US:
This article was originally published in Clinica
Executive Summary
Cygnus has launched its GlucoWatch Biographer in the US. The noninvasive product measures glucose levels frequently and automatically, Cygnus says. There are some 125 million diabetics worldwide - and this figure is expected to double by 2025. In the US around 10 million people have the condition. The Redwood City, California company says the worldwide market for glucose measuring products is estimated at $3-4 billion and expected to reach $4.7 billion in 2002.
You may also be interested in...
Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Horizon's Teprotumumab Breezes Through US FDA Adcom, But Safety Questions Remain
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: